Aligos Therapeutics (5WK0) Price & Analysis

2 Followers

5WK0 Stock Chart & Stats

€3.50

-€0.06(-1.55%)

At close: Jul 28 4:00 PM EDT

€3.50

-€0.06(-1.55%)

Day’s Range― - ―

52-Week Range€3.50 - €11.10

Previous CloseN/A

Volume0.00

Average Volume (3M)1.00

Market Cap

€37.20M

Enterprise Value€33.27

Total Cash (Recent Filing)€30.38M

Total Debt (Recent Filing)€3.50M

Price to Earnings (P/E)―

Beta1.15

Next Earnings

Mar 11, 2027

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-7.30

Shares Outstanding5,444,558

10 Day Avg. Volume0

30 Day Avg. Volume1

Financial Highlights & Ratios

PEG Ratio0.04

Price to Book (P/B)1.72

Price to Sales (P/S)42.14

P/FCF Ratio-1.11

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€62.75

Price Target Upside1692.74% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

EPS Forecast (FY)-5.67

Revenue Forecast (FY)€31.11M

Bulls Say, Bears Say

Bulls Say

High Gross MarginA very high TTM gross margin (~89%) signals strong unit economics on reported revenue. Over the medium term this supports scalability: if development succeeds and revenue grows, the company can leverage high margins to improve profitability faster than peers with lower product-level margins.

Modest LeverageLow debt relative to equity reduces refinancing and solvency risk for a cash-burning biotech. Modest leverage provides financial flexibility to pursue clinical programs or non-dilutive deals, lengthening runway compared with highly leveraged peers during multi-year development cycles.

Non-dilutive Funding And Regulatory MilestonesStructural progress: a $25M upfront license and milestone receipts provide non-dilutive capital while partner IND approval and Breakthrough Designation in China materially de-risk regulatory path. Completed Phase 2 enrollment advances clinical timelines and supports medium-term value creation.

Bears Say

Large Persistent Cash BurnMaterial negative operating and free cash flow every year (TTM about -$94M) means the company cannot self-fund development. Sustained cash burn creates ongoing financing needs, increasing dilution risk and constraining strategic optionality over the next several quarters to years.

Shrinking Revenue And Negative MarginsDeclining TTM revenue coupled with deeply negative net margins indicates the current business scale cannot cover operating expenses. Without durable revenue growth or meaningful expense reduction, structural profitability remains distant and long-term viability depends on successful clinical outcomes or deal flow.

Clinical-stage Business Model DependencyAs a clinical-stage company with no commercial products, Aligos relies on financing, licensing, and partner milestones for cash. This structural dependence increases funding and execution risk: internal cash generation is limited until approval and commercialization occur, raising long-term uncertainty.

Aligos Therapeutics News

Aligos Therapeutics reports Q2 EPS (14c), consensus ($1.38)

Reports Q2 revenue $27.78M, consensus $13.18M. “Our team has continued to execute on our key strategic priorities to...

10d ago

ALGS

Analyst Reiterates Buy on Aligos Therapeutics, Maintains $50 Price Target Amid Strengthened HBV Trial Outlook

Aligos Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Patrick Trucchio from...

1M ago

ALGS

Aligos Therapeutics completes enrollment in B-SUPREME study

Aligos Therapeutics (ALGS) announced that it has completed enrollment of both the HBeAg+ and HBeAg- participants in the...

1M ago

ALGS

Closing Bell Movers: Crinetics doubles on Vertex buyout

Risk-on sentiment resurfaced following the long holiday weekend as large-cap growth areas of the market handily outperformed SMIDs...

1M ago

RTO

STX

Aligos Therapeutics receives $25M upfront for pevifoscorvir sodium license deal

Aligos Therapeutics (ALGS) announced that it has received the upfront payment of $25M from the exclusive license deal...

1M ago

ALGS

Aligos Therapeutics Shareholders Approve Directors and Governance Changes

Aligos Therapeutics ( ($ALGS) ) has provided an announcement. On June 25, 2026, Aligos Therapeutics, Inc. held its...

2M ago

ALGS

Aligos Therapeutics initiated with a Buy at Lake Street

Lake Street analyst Daniel Brims initiated coverage of Aligos Therapeutics (ALGS) with a Buy rating and $45 price...

3M ago

ALGS

Aligos Therapeutics presents data at EASL congress

Aligos Therapeutics (ALGS) announced data from ten presentations at the European Association for the Study of the Liver,...

3M ago

ALGS

Aligos Therapeutics initiated with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald analyst Steve Seedhouse initiated coverage of Aligos Therapeutics (ALGS) with an Overweight rating and $20 price...

3M ago

ALGS

Aligos Therapeutics initiated with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage of Aligos Therapeutics (ALGS) with an Overweight rating and $20 price target Published first...

3M ago

ALGS

Aligos Therapeutics Licenses Hepatitis B Drug Rights to Amoytop

Aligos Therapeutics ( ($ALGS) ) just unveiled an announcement. On April 16, 2026, Aligos Therapeutics entered into a...

4M ago

ALGS

Aligos Therapeutics signs license deal to develop pevifoscorvir in China

Aligos Therapeutics (ALGS) has entered into an exclusive license agreement to develop and commercialize pevifoscorvir sodium with Xiamen...

4M ago

ALGS

Aligos Therapeutics: Data-Driven Phase 2 Update Supports Buy Rating and $50 Target on Pevifoscorvir’s HBV Opportunity

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Aligos Therapeutics today and set a price target...

4M ago

ALGS

Aligos Advances HBV Candidate With Interim Data, Fast Track

Aligos Therapeutics ( ($ALGS) ) has shared an announcement. On April 14, 2026, Aligos Therapeutics reported first interim...

4M ago

ALGS

5WK0 FAQ

What was Aligos Therapeutics’s price range in the past 12 months?

Aligos Therapeutics lowest stock price was €3.50 and its highest was €11.10 in the past 12 months.

What is Aligos Therapeutics’s market cap?

Aligos Therapeutics’s market cap is €37.20M.

When is Aligos Therapeutics’s upcoming earnings report date?

Aligos Therapeutics’s upcoming earnings report date is Mar 11, 2027 which is in 207 days.

How were Aligos Therapeutics’s earnings last quarter?

Aligos Therapeutics released its earnings results on Aug 06, 2026. The company reported -€0.121 earnings per share for the quarter, beating the consensus estimate of -€0.947 by €0.826.

Is Aligos Therapeutics overvalued?

According to Wall Street analysts Aligos Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Aligos Therapeutics pay dividends?

Aligos Therapeutics does not currently pay dividends.

What is Aligos Therapeutics’s EPS estimate?

Aligos Therapeutics’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Aligos Therapeutics have?

Aligos Therapeutics has 5,444,558 shares outstanding.

What happened to Aligos Therapeutics’s price movement after its last earnings report?

Aligos Therapeutics reported an EPS of -€0.121 in its last earnings report, beating expectations of -€0.947. Following the earnings report the stock price went down -0.616%.

Which hedge fund is a major shareholder of Aligos Therapeutics?

Currently, no hedge funds are holding shares in DE:5WK0

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Aligos Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-50.76%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Aligos Therapeutics

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for significant unmet medical needs in both viral and liver diseases. Key candidates in its pipeline include ALG-010133, an s-antigen transport-inhibiting oligonucleotide polymer, which is currently undergoing Phase Ib clinical trials for chronic hepatitis B (CHB). Another asset for CHB, ALG-000184, a capsid assembly modulator, is progressing through Phase I clinical trials. Additionally, Aligos is advancing ALG-020572, an antisense oligonucleotide designed to stop HBsAg translation and secretion. Its portfolio also features siRNA drug candidates, including ALG-125755, ALG-125097, and ALG-125819, which have demonstrated potent capabilities in inhibiting HBsAg release from HBV-infected cells. For non-alcoholic steatohepatitis (NASH), the company is developing ALG-055009, a small molecule THR-ß agonist, now in Phase 1a/1b studies. Aligos has also forged several strategic alliances. These include licensing and collaboration with Luxna Biotech Co., Ltd. for HBV genome-targeting oligonucleotides, a partnership with Emory University for HBV capsid assembly modulator technology, an agreement with Katholieke Universiteit Leuven for the development of coronavirus protease inhibitors, and a deal with Merck to research and develop NASH-focused oligonucleotides. Established in 2018, Aligos Therapeutics is headquartered in South San Francisco, California.

Aligos Therapeutics (5WK0) Earnings & Revenues

Historic Earnings Reports

5WK0 Stock 12 Month Forecast

Average Price Target

€62.75

▲(1692.74% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"€2","77":"€77","152":"€152","39.5":"€39.5","114.5":"€114.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":151.45548775,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€151.46</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":62.745844925,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€62.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17.3091986,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€17.31</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,39.5,77,114.5,152],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.705,15.070422134615384,26.43584426923077,37.80126640384615,49.166688538461536,60.53211067307692,71.8975328076923,83.26295494230769,94.62837707692307,105.99379921153846,117.35922134615384,128.72464348076923,140.09006561538462,{"y":151.45548775,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.705,8.24660345576923,12.788206911538461,17.329810367307694,21.87141382307692,26.413017278846155,30.954620734615382,35.496224190384616,40.03782764615384,44.57943110192308,49.121034557692305,53.66263801346153,58.204241469230766,{"y":62.745844925,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.705,4.751476815384615,5.79795363076923,6.844430446153846,7.8909072615384614,8.937384076923077,9.983860892307693,11.030337707692308,12.076814523076923,13.123291338461538,14.169768153846153,15.216244969230768,16.262721784615387,{"y":17.3091986,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.25,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.85,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.1,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.55,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.75,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.3,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.01,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.94,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.705,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >